Email: cspc@cspc.cn
News
October 20, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Next: VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION ACCEPTED BY THE NMPA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us